Brokerages Expect Aduro BioTech Inc (ADRO) Will Announce Earnings of -$0.33 Per Share

Wall Street brokerages expect that Aduro BioTech Inc (NASDAQ:ADRO) will report earnings of ($0.33) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Aduro BioTech’s earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.29). Aduro BioTech posted earnings of ($0.27) per share during the same quarter last year, which suggests a negative year over year growth rate of 22.2%. The company is expected to report its next earnings report on Wednesday, August 1st.

On average, analysts expect that Aduro BioTech will report full-year earnings of ($1.28) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($1.01). For the next financial year, analysts anticipate that the company will report earnings of ($1.08) per share, with EPS estimates ranging from ($1.51) to $0.03. Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Aduro BioTech.

Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported ($0.28) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.07. Aduro BioTech had a negative net margin of 455.58% and a negative return on equity of 39.00%. The firm had revenue of $6.63 million for the quarter, compared to analyst estimates of $3.88 million.

A number of research firms recently weighed in on ADRO. BidaskClub raised shares of Aduro BioTech from a “hold” rating to a “buy” rating in a research note on Saturday, May 12th. HC Wainwright set a $10.00 target price on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Thursday, May 3rd. ValuEngine downgraded shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Friday, April 6th. Finally, Zacks Investment Research downgraded shares of Aduro BioTech from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $13.92.

In other Aduro BioTech news, CEO Stephen T. Isaacs sold 40,000 shares of the stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $8.01, for a total value of $320,400.00. Following the completion of the sale, the chief executive officer now owns 211,434 shares in the company, valued at $1,693,586.34. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Elsas Andrea Van sold 6,874 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.48, for a total transaction of $44,543.52. Following the completion of the sale, the insider now owns 216,669 shares of the company’s stock, valued at approximately $1,404,015.12. The disclosure for this sale can be found here. Insiders have sold 158,925 shares of company stock valued at $1,332,336 in the last 90 days. 5.00% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc increased its position in Aduro BioTech by 105.3% during the first quarter. Legal & General Group Plc now owns 22,233 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 11,405 shares during the period. Foundry Partners LLC increased its position in Aduro BioTech by 31.4% during the first quarter. Foundry Partners LLC now owns 114,028 shares of the biotechnology company’s stock worth $1,060,000 after acquiring an additional 27,230 shares during the period. Millennium Management LLC increased its position in Aduro BioTech by 329.7% during the first quarter. Millennium Management LLC now owns 1,282,347 shares of the biotechnology company’s stock worth $11,926,000 after acquiring an additional 983,906 shares during the period. Barclays PLC increased its position in Aduro BioTech by 125.1% during the first quarter. Barclays PLC now owns 68,887 shares of the biotechnology company’s stock worth $641,000 after acquiring an additional 38,288 shares during the period. Finally, Sofinnova Ventures Inc bought a new position in Aduro BioTech during the first quarter worth about $155,000. 47.26% of the stock is currently owned by institutional investors.

Shares of ADRO traded down $0.15 on Friday, reaching $7.95. 5,000 shares of the company’s stock were exchanged, compared to its average volume of 539,313. The company has a market cap of $653.46 million, a price-to-earnings ratio of -5.53 and a beta of 2.10. Aduro BioTech has a 12 month low of $8.10 and a 12 month high of $8.35.

About Aduro BioTech

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Get a free copy of the Zacks research report on Aduro BioTech (ADRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply